Discovery on Target 2015

The microbiome R&D is an emerging area of science that is starting to prove its importance. Basic and applied biomedical research from the Human Microbiome Project and other independent studies prove that a disruption of a stable microbiome ecosystem results in dysbioses. This imbalance leads to chronic disease and health conditions like inflammation, metabolic disorders, gut disorders, obesity, Type 2 Diabetes, autoimmune disorders, inflammatory bowel disease, neurodevelopmental disorders and more. Additionally, a PubMed search on the term “human microbiome” yielded 300 citations in 2003 and 4,498 citations in 2013. A fair amount of partnerships and commercial ventures have developed during recent years to identify and develop therapies and biomarkers for a number of chronic diseases and health conditions. There is great promise in correlating the microbiome compositions with these disease as well as identifying causes and cures for them. Cambridge Healthtech Institute’s Inaugural conference, Targeting the Microbiome, tracks the scientific and clinical research and applications being made in microbial targeted therapies for inflammation, metabolic disorders, immune disorders and other indications. Through interactive sessions and panel discussions, leading researchers and thought leaders will discuss how their work in this field has and will continue to have tremendous impact in generating personalized diagnostics and therapeutics to improve disease treatment and health maintenance.